Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
Overview of BioHarvest Sciences Inc
BioHarvest Sciences Inc (NASDAQ: BHST, CSE: BHSC, FSE: 8MV0) is a pioneering biotechnology company that leverages its patented Botanical Synthesis technology to produce plant-based molecules without the need to grow the entire plant. By harnessing advanced bio-cell growth processes, BioHarvest develops and manufactures active plant ingredients and therapeutic compounds on an industrial scale. This innovative platform supports dual business verticals in the nutraceutical health and wellness sector as well as in Contract Development and Manufacturing Organization (CDMO) services, making it a unique player in the field of science-based therapeutic solutions.
Innovative Botanical Synthesis Technology
At the core of BioHarvest’s operations is its proprietary Botanical Synthesis technology. This process enables the production of complex, bioactive plant molecules in a controlled, scalable, and sustainable environment. The technology transforms how active ingredients are extracted and synthesized by bypassing traditional agriculture, thereby reducing resource intensity and environmental impact. The company’s method not only ensures consistency in quality but also facilitates the production of patentable molecules that can be tailored to specific medical and nutritional applications.
Dual Business Verticals and Market Positioning
BioHarvest operates within two distinct yet complementary domains:
- Nutraceutical Health and Wellness Products: The company develops and markets proprietary dietary supplements and nutraceutical products that cater to consumer demand for science-based, clinically validated ingredients. Its products, built on botanical synthesis, offer an innovative approach to improving cardiovascular and overall metabolic health.
- Contract Development and Manufacturing Organization (CDMO) Services: Leveraging its cutting-edge technology, BioHarvest partners with other companies in the pharmaceutical, cosmetics, and nutrition industries. This division focuses on the research, development, and production of plant-derived active pharmaceutical ingredients (APIs), fulfilling complex molecules that traditional methods cannot efficiently produce.
This diversified business model strengthens BioHarvest’s market positioning by addressing both end-user consumer products and B2B contract services, thereby opening multiple revenue streams while underscoring their core technological prowess.
Scientific and Technological Expertise
BioHarvest’s process is grounded in rigorous research and years of dedicated R&D, reflecting its deep expertise in biotechnology and bioengineering. The company’s methodology mimics and amplifies natural plant processes, producing molecules that carry the full spectrum of phyto-nutrients. This not only provides enhanced functionality in dietary supplements but also paves the way for the creation of new, patentable compounds with significant therapeutic potential. Such detailed understanding and innovation in the production of bioactive compounds establishes BioHarvest as a credible and authoritative figure in the biotechnological landscape.
Strategic Partnerships and Industry Impact
An important aspect of BioHarvest’s strategy is its collaboration with globally recognized partners. Its recent engagement with a major ingredient solutions provider highlights the company’s commitment to applying botanical synthesis technology to develop next-generation plant-based sweeteners and other compounds. These partnerships allow BioHarvest to integrate its technology into broader food, pharmaceutical, and consumer health contexts, thereby forging a path toward improved access to affordable and nutritious ingredients.
Operational Excellence and Sustainable Production
Beyond innovation, BioHarvest exemplifies operational excellence with a focus on constant improvement and lean production processes. Through investments in digitized manufacturing and enhanced R&D infrastructure, the company ensures that its plant cell growth platform not only meets current market needs but is also positioned to adapt to evolving industry demands. The emphasis on sustainability, resource optimization, and methodological precision highlights BioHarvest’s commitment to delivering high-quality, repeatable outcomes in its manufacturing processes.
Investor-Centric and Research-Driven Insights
For investors and industry analysts, BioHarvest offers a compelling narrative built on scientific rigor, a unique production model, and a diversified approach to product and service offerings. Its methodologies and operational strategies are deeply rooted in a sound technological foundation, providing transparency and reliability in an industry that demands both innovation and accountability.
Overall, BioHarvest Sciences Inc is not only transforming the production of plant-derived bioactive compounds but is also setting new benchmarks in the field of biotechnology and scientific innovation. Its comprehensive approach—from research and development to strategic partnerships and scalable manufacturing—positions the company as a key facilitator of breakthroughs in health and wellness technologies.
BioHarvest Sciences (NASDAQ: BHST) reported strong Q4 2024 financial results with revenues growing 62% to $7.3 million, exceeding guidance. Full-year 2024 revenues increased 99% to $25.2 million with gross margins expanding 1,000 basis points to 55%.
Key highlights include a CDMO partnership with Tate & Lyle for plant-based sweeteners development, successful Nasdaq Global Market uplisting, and VINIA® subscribers surpassing 50,000. The company launched VINIA® SuperFood tea line following successful coffee line introduction which generated $2.3 million since December 2023.
Q4 gross profit increased 80% to $4.1 million (56.7% margin), while marketing expenses decreased to 40.4% of revenue. Management projects Q1 2025 revenues of at least $7.8 million and expects adjusted EBITDA breakeven in H2 2025. The company ended Q4 with $2.4 million cash, subsequently raising $3.9 million in debt financing.
BioHarvest Sciences (NASDAQ: BHST) has scheduled its Q4 and full year 2024 earnings release for March 31, 2025, after market close. The company will host an investor conference call and webcast at 4:30 p.m. Eastern time on the same day.
The earnings call will include a discussion of financial results, corporate updates, and a Q&A session. Participants can join using U.S./Canada dial-in (1-844-825-9789) or International dial-in (1-412-317-5180) with Conference ID 10197712. A replay will be available through April 14, 2025, using pin number 10197712.
BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA. CEO Ilan Sobel will conduct one-on-one meetings with institutional investors throughout the event.
The company, which pioneers the patented Botanical Synthesis technology platform, views this as a significant opportunity to showcase its growth trajectory. Following their Nasdaq listing and the launch of their CDMO Services Division, BioHarvest has achieved notable milestones, including:
- VINIA product reaching $50 Million in cumulative sales
- Advancement in CDMO Services division research for plant-based solutions
- Partnerships with pharmaceutical, nutraceutical, cosmetics, and nutrition sectors
BioHarvest Sciences (NASDAQ: BHST) has announced promising in vitro test results for their proprietary Olive Cell compound, showing reduced fat accumulation in human liver cells. The compound, rich in Verbascoside, demonstrated effectiveness in mitigating fat accumulation in liver steatosis and fibrosis models.
The development targets Non-Alcoholic Fatty Liver Disease (NAFLD), which affects 30-40% of U.S. adults, with its severe form NASH impacting 3-5% of the adult population. The company plans to launch the Olive Cell product as a nutraceutical in 2026, while exploring pharmaceutical partnerships.
The tests, conducted on human hepatic cells, showed the compound's ability to reduce collagen type 1 levels in XL-2 cells. This product will join VINIA® in BioHarvest's portfolio, which has already achieved over $50M USD in sales with 50,000+ active subscribers.
BioHarvest Sciences (NASDAQ: BHST) announced that sales of its flagship product VINIA, a red grape cell-based supplement, have exceeded $50 million USD in cumulative sales. The majority of these sales occurred since the US launch less than 4 years ago.
The company has achieved over 50,000 active U.S. users on recurring subscription packages, with VINIA receiving approximately 8,000 customer reviews and a verified rating of 4.8/5. Clinical trials have demonstrated VINIA's ability to improve blood flow and arterial dilation.
To support future growth, BioHarvest plans to expand its production capacity by 4x with a new 100-ton per year facility, expected to be operational in late 2026. The company has invested 15 years and over $100M in developing its patented Botanical Synthesis technology, which is now being used in their CDMO Services division for pharmaceutical and nutrition industry partners.
BioHarvest Sciences (NASDAQ: BHST) has announced its participation in the upcoming WeBull Consumer Stocks Virtual Webinar on February 18, 2025, at 2:00 p.m. Eastern time. CEO Ilan Sobel will present the company's investor story, focusing on their patented Botanical Synthesis technology platform.
The presentation will showcase BioHarvest's approach to developing and commercializing plant-based compounds, highlighting the growth of their direct-to-consumer business, including the VINIA® product line, and their CDMO Services business unit. The company aims to demonstrate how their technology impacts various industries, including Nutraceuticals, Pharmaceuticals, Cosmeceuticals, and Nutrition, through the delivery of consistent, economically viable, and patentable plant compounds.
The webinar requires mandatory pre-registration, and a replay link will be available on BioHarvest's investor relations website following the event.
BioHarvest Sciences (NASDAQ: BHST) has appointed Sharon Malka as an independent director, effective immediately. Malka brings over 25 years of financial and capital markets experience to the board. He currently serves as CEO of Dotz Nano and is on the board of MediWound , where he previously held positions as CFO and CEO.
Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division, highlighted Malka's operational experience in advancing innovative technologies and structuring strategic transactions as valuable assets for the company's growth. Malka, a certified CPA with an MBA and Harvard Business School Executive Education, expressed enthusiasm about contributing to BioHarvest's development of science-based therapeutic solutions using its Botanical Synthesis technology.
BioHarvest Sciences (NASDAQ: BHST) released a shareholder letter highlighting key achievements in 2024 and outlook for 2025. The company introduced its new CDMO Services division, partnering with Tate & Lyle for sweetener development. The VINIA® capsule business doubled, with approximately 50,000 active U.S. subscribers and a Q4 2024 run rate of nearly $30 million.
Key developments include the launch of VINIA® Functional Superfood Coffee line, generating $1.6 million in sales since launch, and the acquisition of an 80,000 square foot corporate campus in Yavneh, Israel. Gross margins improved from 44% in Q3 2023 to 56% in Q3 2024, with expectations to exceed 60% in 2025. The company successfully uplisted to Nasdaq and targets adjusted EBITDA profitability in H2 2025.
Tate & Lyle and BioHarvest Sciences (NASDAQ: BHST) have announced a strategic partnership to develop next-generation plant-based ingredients for healthier food and beverages. The collaboration will initially focus on developing botanical sweetening ingredients using BioHarvest's proprietary Botanical Synthesis platform, which produces non-GMO plant-derived ingredients by growing targeted plant cells that mirror and magnify phyto-nutrients without traditional farming.
The partnership aims to create sugar-like sweeteners without aftertaste while using significantly less land and water compared to traditional methods. Tate & Lyle will contribute its sugar reduction expertise, regulatory knowledge, and global customer access, while BioHarvest brings its validated industrial-scale plant cell technology. The collaboration is part of Tate & Lyle's open innovation program to create cutting-edge solutions for the food and beverage industry.
BioHarvest Sciences reported strong Q3 2024 financial results with revenue increasing 101% year-over-year to $6.5 million. Gross margins expanded significantly by 1,200 basis points to 57% compared to 45% in the same year-ago quarter. The company's VINIA® subscribers grew 128% year-over-year, and they successfully launched a new VINIA® SuperFood tea line. Management expects Q4 2024 revenues of at least $7.2 million and projects reaching adjusted EBITDA breakeven in H2 2025. The company recently uplisted to the Nasdaq Global Market on November 12, 2024.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
What is the core technology behind BioHarvest Sciences Inc?
How does BioHarvest generate revenue?
What makes BioHarvest’s approach unique in the biotechnology industry?
Who are the typical customers for BioHarvest?
What role do strategic partnerships play for BioHarvest?
How does BioHarvest address quality and scalability in its production?
What industries does BioHarvest serve with its technology?
